189269-12-3

Basic information

• Product Name: Benzamide, 4-[(1E)-3-[[[3-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,4-dimeth ylphenyl]-2-thienyl]methyl]amino]-3-oxo-1-propenyl]-N-methyl-
• CAS NO: 189269-12-3
• Molecular Formula: C41H44N2O3SSi
• Molecular Weight: 672.963
• Mol File: 189269-12-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzamide, 4-[(1E)-3-[[[3-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,4-dimeth ylphenyl]-2-thienyl]methyl]amino]-3-oxo-1-propenyl]-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 4-[(1E)-3-[[[3-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,4-dimeth ylphenyl]-2-thienyl]methyl]amino]-3-oxo-1-propenyl]-N-methyl-(189269-12-3)
• EPA Substance Registry System: Benzamide, 4-[(1E)-3-[[[3-[3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,4-dimeth ylphenyl]-2-thienyl]methyl]amino]-3-oxo-1-propenyl]-N-methyl-(189269-12-3)

Safety Data

• Hazardous Substances Data: 189269-12-3(Hazardous Substances Data)

Upstream product

• 18791-98-5 3-bromo-thiophene-2-carbonitrile 
• 189269-11-2 2-aminomethyl-3-(3-tert-butyldiphenylsilyloxymethyl-2,4-dimethylphenyl)thiophene 
• 179627-11-3 4-(methylcarbamoyl)cinnamic acid 
• 189269-10-1 3-(3-tert-butyldiphenylsilyloxymethyl-2,4-dimethylphenyl)-2-cyanothiophene 

Downstream Products

• 189269-13-4 4-((E)-2-{[3-(3-Hydroxymethyl-2,4-dimethyl-phenyl)-thiophen-2-ylmethyl]-carbamoyl}-vinyl)-N-methyl-benzamide 

Relevant articles and documents

Quinoline derivatives as bradykinin agonists

PCT No. PCT/JP97/00233 Sec. 371 Date Aug. 3, 1998 Sec. 102(e) Date Aug. 3, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/28153 PCT Pub. Date Aug. 7, 1997This invention relates to a compound of formula (1) wherein R1 is halogen, etc., R2 is halogen, etc., R3 is amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, etc., R4 is heterocyclic (lower)alkyl, R5 is lower alkyl, and A1 is lower alkylene, and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation

In recent articles we reported the identification of a series of 8- [[2,6-dichloro-3-[N-methyl-N-[(E)- (substituted)acryloylglycyl]amino]benzyl]oxy]-2-methylimidazo[1,2- a]pyridines as the first orally active non-peptide bradykinin (BK) B2 rece